Table 6.6a

Immunosuppression Use for Induction, 1995 to 2004

Recipients with Pancreas Transplant Alone (PTA) Transplants

  Year of Transplant
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 42 52 79 88 137 135 165 177 159 185
With Immunosuppression Info 41 50 76 80 133 127 157 160 131 170
Induction Drugs 19.5% 4.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 12.2% 22.0% 18.4% 15.0% 8.3% 0.0% 0.0% 0.0% 1.5% 2.4%
OKT3 46.3% 44.0% 39.5% 22.5% 7.5% 4.7% 3.2% 2.5% 0.0% 0.0%
Thymoglobulin 0.0% 0.0% 0.0% 0.0% 30.1% 48.0% 50.3% 58.1% 35.9% 51.2%
Zenapax 0.0% 0.0% 1.3% 31.3% 30.8% 43.3% 35.0% 33.8% 9.9% 9.4%
Simulect 0.0% 0.0% 0.0% 3.8% 11.3% 9.4% 3.2% 4.4% 7.6% 0.0%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.6% 35.1% 42.9%
No Induction Drugs Recorded 26.8% 32.0% 40.8% 41.3% 36.8% 30.7% 38.2% 32.5% 20.6% 18.8%


Source: OPTN/SRTR Data as of May 2, 2005.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.